Effect of rehabilitation therapy on the motor functions in patients with multiple system atrophy
Objective: We aim to evaluated the effect of rehabilitation therapy on the motor symptoms and activities of daily living in patients with MSA using an…TOPAS-MSA: Targeting Oligomer Pathology of Alpha-Synuclein – A Study Evaluating the Safety and Efficacy of Emrusolmin in Patients with Multiple System Atrophy
Objective: The objective of the TOPAS-MSA study is to assess the safety and efficacy of emrusolmin (anle138b/TEV-56286), an orally bioavailable small molecule targeting aggregated α-synuclein,…Safety and Efficacy of the Anti-alpha Synuclein Monoclonal Antibody Lu AF82422 for the Treatment of Patients with MSA: Results from the Phase 2 AMULET Trial
Objective: Assess the efficacy and safety of monthly IV infusions with the anti-alpha synuclein [a-syn] monoclonal antibody Lu AF82422 for the treatment of patients with…Association Between Clinical Progression in Multiple System Atrophy and Brain Volume Changes Evaluated via Deep Learning Segmentation
Objective: Assess brain volume changes in patients with multiple system atrophy (MSA) over one year. Background: Identifying disease progression biomarkers is crucial for advancing MSA…Incorporating the Voice of the Patient and Caregiver into a Multiple System Atrophy (MSA) clinical trial
Objective: To understand patient and caregiver preferences and perceptions of a proposed clinical trial design for an interventional drug targeting Multiple System Atrophy. Background: Stakeholders…A Phase 1b Randomized, Placebo-Controlled, Delayed-Start Trial of UB-312 in Synucleinopathies.
Objective: Assess safety and immunogenicity of UB-312 in a phase 1b trial in Multiple System atrophy (MSA) or Parkinson’s disease (PD). Background: Abnormal deposition of…SNCA Antisense Oligonucleotide for Multiple System Atrophy: HORIZON Trial Update
Objective: To provide an update on the baseline demographics and safety from the HORIZON Clinical Trial of ION464 Background: Multiple System Atrophy (MSA) is a…Long-term Safety of Ampreloxetine in Patients with Symptomatic Neurogenic Orthostatic Hypotension
Objective: To assess the long-term safety and tolerability of ampreloxetine in patients with synucleinopathies (MSA, PD, and PAF) and symptomatic neurogenic orthostatic hypotension (nOH) from…Autoradiography characterization of novel alpha-synuclein radioligands [3H]Tg1-90B, [3H]M503-1619 and [3H]HY-2-15 in human post mortem brain
Objective: To characterize the in vitro binding properties of 3 radioligands for imaging α-syn aggregates in post mortem brain samples of synucleinopathies: [3H]TG-190B (Site 2),…Brain De-Ironization with Nasal Spray of Iron Chelator in Treatment of Multiple System Atrophy, a Case Trial
Objective: Iron removal seems to be a treatment approach in Multiple system atrophy (MSA) because pathological findings shows the accumulation of iron and α-synuclein protein…
- 1
- 2
- 3
- …
- 7
- Next Page »